Public Assessment Report. Decentralised Procedure. Ipravent CFC-Free Inhaler 20 micrograms per actuation pressurised inhalation, solution

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Public Assessment Report. Decentralised Procedure. Ipravent CFC-Free Inhaler 20 micrograms per actuation pressurised inhalation, solution"

Transcription

1 Public Assessment Report Decentralised Procedure Ipravent CFC-Free Inhaler 20 micrograms per actuation pressurised inhalation, solution (ipratropium bromide monohydrate) Procedure No: UK Licence No: PL 36390/0083 Cipla (EU) Limited 1

2 LAY SUMMARY Ipravent CFC-Free Inhaler 20 micrograms per actuation pressurised inhalation, solution (ipratropium bromide monohydrate; pressurised inhalation, solution; 20 micrograms per actuation) This is a summary of the Public Assessment Report (PAR) for Ipravent CFC-Free Inhaler 20 micrograms per actuation pressurised inhalation, solution (PL 36390/0083; ). It explains how Ipravent CFC-Free Inhaler 20 micrograms per actuation pressurised inhalation, solution was assessed and its authorisation recommended, as well as its conditions of use. It is not intended to provide practical advice on how to use Ipravent CFC-Free Inhaler 20 micrograms per actuation pressurised inhalation, solution. For practical information about using Ipravent CFC-Free Inhaler 20 micrograms per actuation pressurised inhalation, solution, patients should read the package leaflet or contact their doctor or pharmacist. The product may be referred to as Ipravent CFC-Free Inhaler in this report. What is Ipravent CFC-Free Inhaler and what is it used for? Ipravent CFC-Free Inhaler contains the active substance ipratropium bromide (as ipratropium bromide monohydrate). Ipravent CFC-Free Inhaler is used to make breathing easier for people with asthma or chronic obstructive pulmonary disease (COPD), often referred to as chronic bronchitis. Ipravent CFC-Free Inhaler is not to be used in children, 12 years of age and younger or adolescents 13 to 17 years of age. Ipravent CFC-Free Inhaler is a hybrid medicine. This means that Ipravent CFC-Free Inhaler contains the same active substance as, and is similar to, a reference medicine already authorised in the European Union (EU) called Atrovent dosis-aërosol 20 μg/dosis, aërosol, oplossing (NL RVG 2683; Boehringer Ingelheim B.V) first approved in the Netherlands in a chlorofluorocarbon (CFC)-free hydrofluoroalkane (HFA)-containing formulation in November The corresponding reference product in the UK is ATROVENT Inhaler CFC-Free 20 micrograms/actuation pressurised inhalation solution (Boehringer Ingelheim Limited, UK; PL 00015/0266), approved in the UK on 01 March How is Ipravent CFC-Free Inhaler used? Ipravent CFC-Free Inhaler is inhaled through the mouth. The product is not to be used with any spacing device. The usual recommended dose is 1 or 2 puffs to be inhaled three or four times daily. However, in early treatment some patients may need up to 4 puffs at a time to obtain maximum effect. The recommended dose should not be exceeded. Ipravent CFC-Free Inhaler can only be obtained on prescription. How does Ipravent CFC-Free Inhaler work? The active substance, ipratropium bromide, belongs to a group of medicines called bronchodilators. In asthma or COPD, patients may have difficulty in breathing, shortness of breath, wheezing or tightness in the chest. Ipravent CFC-Free Inhaler works by opening up airways. 2

3 How has Ipravent CFC-Free Inhaler been studied? As Ipravent CFC-Free Inhaler is a hybrid medicine, studies in patients have been limited to tests to determine it is therapeutically equivalent to the reference medicine, ATROVENT Inhaler CFC-Free 20 micrograms/actuation pressurised inhalation solution (Boehringer Ingelheim Limited, UK). Two medicines are therapeutically equivalent when they produce the same measure of therapeutic effect in the body. In addition the company provided data from the published literature on ipratropium bromide. What are the benefits and risks of Ipravent CFC-Free Inhaler? Because Ipravent CFC-Free Inhaler is a hybrid medicine and is therapeutically equivalent to the reference medicine, its benefits and risks are taken as being the same as those of the reference medicine. Why is Ipravent CFC-Free Inhaler approved? It was concluded that, in accordance with EU requirements, Ipravent CFC-Free Inhaler has been shown to have comparable quality and to be therapeutically equivalent to ATROVENT Inhaler CFC-Free 20 micrograms/actuation pressurised inhalation solution (Boehringer Ingelheim Limited, UK). Therefore, the view was that, as for ATROVENT Inhaler CFC-Free 20 micrograms/actuation pressurised inhalation solution (Boehringer Ingelheim Limited, UK), the benefit outweighs the identified risk. What measures are being taken to ensure the safe and effective use of Ipravent CFC-Free Inhaler? Safety information has been included in the Summary of Product Characteristics and the package leaflet for Ipravent CFC-Free Inhaler, including the appropriate precautions to be followed by healthcare professionals and patients. Other information about Ipravent CFC-Free Inhaler A Marketing Authorisation was granted in the UK on 05 November The full PAR for Ipravent CFC-Free Inhaler follows this summary. For more information about treatment with Ipravent CFC-Free Inhaler, read the package leaflet, or contact your doctor or pharmacist. This summary was last updated in January

4 TABLE OF CONTENTS Module 1: Information about the initial procedure Page 5 Module 2: Summary of Product Characteristics Page 6 Module 3: Patient Information Leaflet Page 7 Module 4: Labelling Page 8 Module 5: Scientific discussion during the initial procedure Page 11 I Introduction II About the product III Scientific overview and discussion III 1 Quality aspects III 2 Non-clinical aspects III 3 Clinical aspects IV Overall conclusion and benefit/risk assessment Module 6: Steps taken after initial procedure Page 18 4

5 Module 1 Information about the initial procedure Product Name Ipravent CFC-Free Inhaler 20 micrograms per actuation pressurised inhalation, solution Type of Application Generic, Article 10(3) Active Substance Ipratropium bromide (as ipratropium bromide monohydrate) Form Pressurised inhalation, solution Strength MA Holder 20 micrograms per actuation Cipla (EU) Limited Hillbrow House Hillbrow Road Esher Surrey KT10 9NW United Kingdom Reference Member State (RMS) UK Concerned Member State (CMS) Ireland Procedure Number Timetable Day October

6 Module 2 Summary of Product Characteristics In accordance with Directive 2010/84/EU, the Summaries of Product Characteristics (SmPCs) for products granted Marketing Authorisations at a national level are available on the MHRA website. 6

7 Module 3 Patient Information Leaflet In accordance with Directive 2010/84/EU, the Patient Information Leaflets (PILs) for products granted Marketing Authorisations at a national level are available on the MHRA website. 7

8 Module 4 Labelling The Marketing Authorisation Holder has submitted the text version only and has committed to submitting mock-up livery to the relevant regulatory authorities for approval before packs are marketed. 8

9 9

10 10

11 Module 5 Scientific discussion during initial procedure I INTRODUCTION Based on the review of the data on quality, safety and efficacy, the UK and Ireland considered that the application for Ipravent CFC-Free Inhaler 20 micrograms per actuation pressurised inhalation, solution (PL 36390/0083; ) could be approved. Ipravent CFC-Free Inhaler 20 micrograms per actuation pressurised inhalation, solution may be referred to as Ipravent CFC free Inhaler in this report. The product is a prescription-only medicine (POM). Ipravent CFC free Inhaler is indicated for the regular treatment of reversible bronchospasm associated with chronic obstructive pulmonary disease (COPD) and chronic asthma. Ipravent CFC free Inhaler is not indicated for use in children, 12 years of age and younger or adolescents 13 to 17 years of age. The product is not to be used with any spacing device. If a spacing device is required, the patient s inhaler treatment will have to be changed to an alternative inhaler that can be used with a spacing device. The applicant has provided a post-authorisation commitment to develop a spacing device for use with Ipravent CFC free Inhaler. The application was submitted using the Decentralised Procedure (DCP), with the UK as Reference Member State (RMS) and Ireland as Concerned Member State (CMS). The application was submitted under Article 10(3) of Directive 2001/83/EC, as amended, as a hybrid application. The reference medicinal product for this application is Atrovent dosis-aërosol 20 μg/dosis, aërosol, oplossing (Boehringer Ingelheim B.V., Netherlands) first approved in the Netherlands on 14 November The corresponding reference product in the UK is ATROVENT Inhaler CFC-Free 20 micrograms/actuation pressurised inhalation, solution (PL 00015/0266; Boehringer Ingelheim Limited, UK), which was approved in the UK on 01 March Prior to March 2004, Atrovent (ipratropium bromide) had been available in the UK as a CFC-containing pressurised metered dose inhaler (pmdi; Marketing Authorisation Holder: Boehringer Ingelheim Limited, UK), which has been replaced with the CFC-free, HFA-containing, orally inhaled reference product. Ipravent CFC-Free Inhaler 20 micrograms per actuation pressurised inhalation, solution contains the active ingredient, ipratropium bromide (as ipratropium bromide monohydrate), a quaternary ammonium compound. Ipratropium bromide is a synthetic anticholinergic agent which acts as a non-selective antagonist at the muscarinic receptor. When inhaled orally, ipratropium bromide blocks M1, M2 and M3 muscarinic receptors located on airway smooth muscle, producing relaxation of smooth muscle and bronchodilation. Bronchodilation is primarily a local effect and is not due to systemic absorption. Ipratropium bromide is a short-acting bronchodilator. A single-dose pharmacokinetic (bioequivalence) study was submitted to support this application, comparing the applicant s test product Ipratropium bromide HFA pmdi (containing ipratropium bromide 20 micrograms/actuation) with the reference product Atrovent CFC-free (containing ipratropiun bromide 20 micrograms/actuation; Boehringer Ingelheim Limited, UK) in healthy adult male human subjects under fasting conditions. The study was conducted according to the current version of the Principles of Declaration of Helsinki (Revised Seoul, October 2008) and in compliance with the current ICH GCP, OECD GLP, National Regulations (ICMR Guidelines), Indian GCP and Schedule Y of Indian Drugs and Cosmetic Act, the European Guideline on bioequivalence (CPMP/QWP/EWP/1401/98 Rev. 1, dated January 2010) and the CHMP Guideline on orally inhaled products (CPMP/EWP/4151/00 Rev. 1, dated January 2009). With the exception of the clinical pharmacokinetic study, no new non-clinical or clinical efficacy studies were performed for this application, which is acceptable given that this is a hybrid application based on 11

12 an originator product that has been in clinical use for over 10 years. The non-clinical dossier consists of published literature and this is acceptable. The RMS has been assured that acceptable standards of Good Manufacturing Practice (GMP) are in place at all sites responsible for the manufacture, assembly and batch release of this product. For manufacturing sites within the Community, the RMS has accepted copies of current manufacturer authorisations issued by inspection services of the competent authorities as certification that acceptable standards of GMP are in place at those sites. The RMS and CMS considered that the application could be approved at the end of procedure (Day 210) on 06 October After a subsequent national phase, a licence was granted in the UK on 05 November II. ABOUT THE PRODUCT Name of the product in the Reference Ipravent CFC-Free Inhaler 20 micrograms per Member State actuation pressurised inhalation, solution Name(s) of the active substance(s) (INN) Ipratropium bromide (as ipratropium bromide monohydrate) Pharmacotherapeutic classification Anticholinergic bronchodilator (ATC code) (ATC code: R03B B01) Pharmaceutical form and strength Pressurised inhalation, solution; 20 micrograms per actuation Reference number for the Decentralised Procedure Reference Member State (RMS) United Kingdom Concerned Member States (CMS) Ireland Marketing Authorisation Number PL 36390/0083 Name and address of the authorisation Cipla (EU) Limited holder Hillbrow House Hillbrow Road Esher Surrey KT10 9NW United Kingdom III SCIENTIFIC OVERVIEW AND DISCUSSION III.1 QUALITY ASPECTS ACTIVE SUBSTANCE INN: Ipratropium bromide Chemical Name: (1R,3r,5S,8r)-3-[(RS)- (3-hydroxy-2-phenylpropanoyl)oxy]-8-methyl-8-(1 -methylethyl)-8- azoniabicyclo[3.2.1]octane bromide Molecular formula: C 20 H 30 BrNO 3 H 2 O Structure: Molecular mass: Appearance: A white or almost white crystalline powder Solubility: Soluble in water, freely soluble in methanol and slightly soluble in ethanol. 12

13 Ipratropium bromide is the subject of a European Pharmacopoeia monograph. All aspects of the manufacture and control of the active substance, ipratropium bromide, are covered by a European Directorate for the Quality of Medicines and Healthcare (EDQM) Certificate of Suitability. MEDICINAL PRODUCT Other Ingredients Other ingredients consist of the pharmaceutical excipients 1, 1, 1, 2-tetrafluoroethane (HFA 134a), ethanol anhydrous, purified water and citric acid anhydrous. Appropriate justification for the inclusion of each excipient has been provided. All excipients comply with their respective European Pharmacopoeia monographs, with the exception of 1, 1, 1, 2-tetrafluoroethane (HFA 134a) which is controlled to a suitable in-house specification. Certificates of Analysis have been provided for all excipients, showing compliance with their respective specifications. None of the excipients contain materials of animal or human origin. No genetically modified organisms (GMO) have been used in the preparation of these excipients. Pharmaceutical Development The objective of the pharmaceutical development programme was to produce a safe, efficacious pressurised inhalation, solution that was comparable in performance to the originator product, Atrovent Inhaler CFC-Free 20 micrograms/actuation pressurised inhalation, solution (Boehringer Ingelheim Limited). Suitable pharmaceutical development data have been provided for this application. Comparative in-vitro data have been provided for this product and the reference product. Manufacturing Process A satisfactory batch formula has been provided for the manufacture of the product, along with an appropriate account of the manufacturing process. The manufacturing process has been validated with full production-scale batches that have shown satisfactory results. Control of Finished Product The finished product specification is acceptable. Test methods have been described and have been validated adequately. Batch data have been provided, which comply with the release specification. Certificates of Analysis have been provided for all working standards used. Container-Closure System The product is supplied in 19 ml pressurised pure aluminium anodized canisters (containing 12.8 ml of solution) sealed with 50 µl metering valves made up of thermoplastic and plastic actuators made up of polypropylene, having white mouthpieces fitted with green mouthpiece covers. The product is available in a pack size of one canister. Each canister contains 200 metered actuations of 20 micrograms of ipratropium bromide. Satisfactory specifications and Certificates of Analysis for the primary packaging material have been provided. All primary packaging is controlled to European Pharmacopoeia standards that comply with guidance concerning materials in contact with foodstuff. 13

14 Stability of the Product Finished product stability studies were performed in accordance with current guidelines on batches of finished product in the packaging proposed for marketing. The data from these studies support a shelf-life of 24 months, with the storage instructions Do not store above 25 C. Protect from direct sunlight, heat and frost. The canister contains a pressurised liquid. Do not expose to temperatures higher than 50 C. Do not pierce the canister. Suitable post approval stability commitments have been provided to continue stability testing on batches of finished product. Bioequivalence/Bioavailability Satisfactory Certificates of Analysis have been provided for the test and reference batches used in the bioequivalence study. The bioequivalence study is discussed in Section III.3, Clinical Aspects. Summary of Product Characteristics (SmPC), Product Information Leaflet (PIL) and Labels The SmPC, PIL and labels are satisfactory from a pharmaceutical perspective. Final text versions of the labelling and PIL have been provided. The Marketing Authorisation Holder has committed to submitting mock-ups to the relevant competent authorities for approval before marketing any pack size. Marketing Authorisation Application (MAA) Form The MAA form is satisfactory from a pharmaceutical perspective. Expert Report (Quality Overall Summary) The quality overall summary has been written by an appropriately qualified person and is a suitable summary of the pharmaceutical aspects of the dossier. Conclusion The grant of a Marketing Authorisation is recommended. III.2 NON-CLINICAL ASPECTS As the pharmacodynamic, pharmacokinetic and toxicological properties of ipratropium bromide are well-known, no new non-clinical data have been submitted and none are required. The applicant s non-clinical expert report has been written by an appropriately qualified person and is satisfactory, providing an appropriate review of the relevant non-clinical pharmacology, pharmacokinetics and toxicology. Suitable justification has been provided for non-submission of an Environmental Risk Assessment. As the application is to substitute for an already authorised product, it is not expected that environmental exposure will increase following approval of the Marketing Authorisation for the proposed product. The grant of a Marketing Authorisation is recommended. III.3 CLINICAL ASPECTS Clinical Pharmacololgy The clinical pharmacology of ipratropium bromide is well-known. With the exception of data from the pharmacokinetic study detailed below, no new pharmacodynamic or pharmacokinetic data are provided or required for this application. In support of the application, the Marketing Authorisation Holder submitted the following pharmacokinetic (bioequivalence) study to demonstrate therapeutic equivalence between the test product and the reference product. The CHMP Guideline for orally inhaled products (CPMP/EWP/4151/00 14

15 Rev. 1) states that pharmacokinetic studies should be carried out in the intended patient population; the applicant has provided suitable justification for carrying out the study in healthy adult volunteers. A randomised, single dose, open label, two-treatment, two-period, two-sequence, crossover bioequivalence study comparing the test product Ipratropium bromide HFA pmdi (containing ipratropium bromide 20 micrograms/actuation; Cipla Limited) with the reference product Atrovent CFC-free (containing ipratropiun bromide 20 micrograms/actuation; Boehringer Ingelheim Limited, UK), both administered as 4 puffs in healthy adult male human subjects under fasting conditions. The subjects self-administered (orally inhaled) a single dose (4 x 20 micrograms per actuation/puff; 80 micrograms) of either the test or the reference product on the two treatment days in a cross-over fashion as per the randomisation sequence, after at least a 10-hour overnight fast. A dose of 80 micrograms was chosen as 80 micrograms is the highest recommended single dose of the reference product. Spacing devices were not used. Blood samples were collected pre-dose and up to 24 hours after each administration. The washout period between the treatment arms was six days. The pharmacokinetic results are presented below. Pharmacokinetic parameters (geometric means, ratios and 90% confidence intervals (CI)) for ipratropium bromide Pharmacokinetic Geometric Mean *(%)T/R 90% Confidence Parameters Test (T) Reference (R) Interval C max (pg/ml) AUC 0-t (hr.pg/ml) C max maximum plasma concentration AUC 0-t area under the plasma concentration-time curve from time zero to t hours *(%) T/R is ratio Test Geometric Least Square Mean/Reference Geometric Least Square Mean Ratios and 90% CI calculated from ln-transformed data Conclusion of study The pharmacokinetic parameters measured in this study are appropriate parameters to measure in the assessment of therapeutic equivalence between two orally inhaled products. The pulmonary available dose is reflected through measurement of AUO 0-t and the regional pulmonary deposition through the measurement of C max. The results demonstrate that the pulmonary available dose (via AUO 0-t ) and regional lung deposition (via C max ) are similar between the test and reference product. The 90% CI for the least square mean ratio of the test product to the reference product for both AUO 0-t and C max lie within the acceptable limits of 80.00% to %, in line with the Guideline on the Investigation of Bioequivalence (CPMP/EWP/QWP/1401/98 Rev 1/Corr**). Thus, the data support the claim that the applicant s test product is bioequivalent to, and thus therapeutically equivalent to, the reference product under fasting conditions. Efficacy The efficacy of ipratropium bromide is well-known. No new efficacy data have been submitted and none are required for this type of application. 15

16 Safety With the exception of the safety data generated during the bioequivalence study, no new safety data were submitted and none are required for this type of application. No new or unexpected safety issues arose during the bioequivalence study. Summary of Product Characteristics (SmPC), Patient Information Leaflet (PIL) and Labels The SmPC, PIL and labels are acceptable from a clinical perspective. The PIL is consistent with the details in the SmPC and in line with current guidance. The labelling is in line with current guidance. Clinical Expert Report (Clinical Overview) The clinical overview has been written by an appropriately qualified physician and is a suitable summary of the clinical aspects of the dossier. Pharmacovigilance System and Risk Management Plan The Pharmacovigilance System, as described by the MAH, fulfils the requirements and provides adequate evidence that the MAH has the services of a qualified person responsible for pharmacovigilance, and has the necessary means for the notification of any adverse reaction suspected of occurring either in the Community or in a third country. Suitable justification has been provided for non-submission of a Risk Management Plan (RMP) for this application which was received prior to the date (21 July 2012) when the pharmacovigilance regulations in accordance with Directive 2010/84/EU came into force. Conclusion The grant of a Marketing Authorisation is recommended. IV OVERALL CONCLUSION AND BENEFIT/RISK ASSESSMENT QUALITY The important quality characteristics of Ipravent CFC-Free Inhaler 20 micrograms per actuation pressurised inhalation, solution are well-defined and controlled. The specifications and batch analytical results indicate consistency from batch to batch. There are no outstanding quality issues that would have a negative impact on the benefit/risk balance. NON-CLINICAL No new non-clinical data were submitted. As the pharmacokinetics, pharmacodynamics and toxicology of ipratropium bromide are well-known, no additional data were required. EFFICACY With the exception of the bioequivalence study, no new data were submitted and none are required for this type of application. Therapeutic equivalence has been demonstrated between the applicant s test product and the reference product Atrovent CFC-free (containing ipratropiun bromide 20 micrograms/actuation; Boehringer Ingelheim Limited, UK). SAFETY With the exception of the safety data generated from the bioequivalence study, no new data were submitted and none are required for this type of application. As the safety profile of ipratropium bromide is well known, no additional safety data were required. No new or unexpected safety concerns arose from the pharmacokinetic study. 16

17 PRODUCT LITERATURE The SmPC, PIL and labelling text is satisfactory and consistent with that for the reference product, where appropriate and are in line with current guidance. BENEFIT/RISK ASSESSMENT The quality of the product is acceptable, and no new non-clinical or clinical safety concerns have been identified. Extensive clinical experience with ipratropium bromide is considered to have demonstrated the therapeutic value of the compound. The benefit/risk balance is, therefore, considered to be positive. 17

18 Module 6 STEPS TAKEN AFTER THE INITIAL PROCEDURE - SUMMARY Date submitted Application type Scope Outcome 18

Levonorgestrel/Ethinylestradiol 150/30 Microgram Coated Tablets PL 20117/0044

Levonorgestrel/Ethinylestradiol 150/30 Microgram Coated Tablets PL 20117/0044 Levonorgestrel/Ethinylestradiol 150/30 Microgram Coated Tablets PL 20117/0044 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 11 Summary of Product

More information

Public Assessment Report. (Budesonide) PL 17901/0254. AstraZeneca UK Ltd

Public Assessment Report. (Budesonide) PL 17901/0254. AstraZeneca UK Ltd Public Assessment Report Rhinocort Hay Fever 64 micrograms, Nasal Spray (Budesonide) PL 17901/0254 AstraZeneca UK Ltd 1 LAY SUMMARY Rhinocort Hay Fever 64 micrograms, Nasal Spray (Budesonide) This is a

More information

Public Assessment Report. Scientific discussion. Desloracell 5 mg, film-coated tablet. (desloratadine) NL License RVG: 112807

Public Assessment Report. Scientific discussion. Desloracell 5 mg, film-coated tablet. (desloratadine) NL License RVG: 112807 Public Assessment Report Scientific discussion Desloracell 5 mg, film-coated tablet (desloratadine) NL License RVG: 112807 Date: 6 July 2015 This module reflects the scientific discussion for the approval

More information

Public Assessment Report. Decentralised Procedure

Public Assessment Report. Decentralised Procedure Public Assessment Report Decentralised Procedure Amlodipine Pfizer 5 mg tablets Amlodipine Pfizer 10 mg tablets Amlodipine Pfizer 5 mg hard capsules Amlodipine Pfizer 10 mg hard capsules Procedure No:

More information

Public Assessment Report UKPAR. Levonorgestrel 1.5 mg tablet. (levonorgestrel). UK Licence No: PL 41947/0006. ELC Group s.r.o.

Public Assessment Report UKPAR. Levonorgestrel 1.5 mg tablet. (levonorgestrel). UK Licence No: PL 41947/0006. ELC Group s.r.o. Public Assessment Report UKPAR Levonorgestrel 1.5 mg tablet (levonorgestrel). UK Licence No: PL 41947/0006 ELC Group s.r.o. 1 LAY SUMMARY Levonorgestrel 1.5 mg tablet (Levonorgestrel, tablet, 1.5 mg) This

More information

STREPSILS BLACKCURRANT FLAVOUR LOZENGES STREPSILS DRY & SORE THROAT BLACKCURRANT FLAVOUR LOZENGES

STREPSILS BLACKCURRANT FLAVOUR LOZENGES STREPSILS DRY & SORE THROAT BLACKCURRANT FLAVOUR LOZENGES STREPSILS BLACKCURRANT FLAVOUR LOZENGES STREPSILS DRY & SORE THROAT BLACKCURRANT FLAVOUR LOZENGES (amylmetacresol, 2,4-dichlorobenzyl alcohol, ascorbic acid and sodium ascorbate) PL 00063/0692 UKPAR TABLE

More information

Beclometasone Dipropionate 50 micrograms per spray Aqueous Nasal Spray PL 16431/0178

Beclometasone Dipropionate 50 micrograms per spray Aqueous Nasal Spray PL 16431/0178 Beclometasone Dipropionate 50 micrograms per spray Aqueous Nasal Spray PL 16431/0178 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific Discussion Page 5 Steps Taken for Assessment Page 11 Steps Taken

More information

Public Assessment Report. Decentralised Procedure

Public Assessment Report. Decentralised Procedure Public Assessment Report Decentralised Procedure LANSOPRAZOLE 15 MG AND 30 MG ORODISPERSIBLE TABLETS (lansoprazole) Procedure No: UK Licence No: PL 35507/0118-0119 Lupin (Europe) Limited LAY SUMMARY Lansoprazole

More information

LEMSIP MAX DAY & NIGHT COLD & FLU RELIEF CAPSULES. (paracetamol, caffeine and phenylephrine hydrochloride)

LEMSIP MAX DAY & NIGHT COLD & FLU RELIEF CAPSULES. (paracetamol, caffeine and phenylephrine hydrochloride) LEMSIP MAX DAY & NIGHT COLD & FLU RELIEF CAPSULES (paracetamol, caffeine and phenylephrine hydrochloride) PL 00063/0529 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific Discussion Page 5 Summary of

More information

Public Assessment Report. Decentralised Procedure

Public Assessment Report. Decentralised Procedure Public Assessment Report Decentralised Procedure Opticrom Allergy Single Dose 2% w/v Eye Drops, Solution (sodium cromoglicate) Procedure No: UK Licence No: PL 04425/0688 Aventis Pharma Limited (T/A Sanofi-aventis

More information

Decentralised Procedure. Public Assessment Report

Decentralised Procedure. Public Assessment Report Decentralised Procedure Public Assessment Report Articainhydrochlorid mit Epinephrin Pierrel 40 mg/ml + 0.01 mg/ml Injektionslösung Articainhydrochlorid mit Epinephrin Pierrel 40 mg/ml + 0.005 mg/ml Injektionslösung

More information

PUBLIC ASSESSMENT REPORT Scientific Discussion. Perindopril arginine Amlodipine FR/H/325-326-327/01-04/DC. Applicant: Servier

PUBLIC ASSESSMENT REPORT Scientific Discussion. Perindopril arginine Amlodipine FR/H/325-326-327/01-04/DC. Applicant: Servier Direction de l Evaluation des Médicaments et des Produits Biologiques PUBLIC ASSESSMENT REPORT Scientific Discussion COVERAM PERINDOPRIL ARGININE - AMLODIPINE SERVIER PERINDOPRIL ARGININE AMLODIPINE BIOPHARMA

More information

Compilation of individual product-specific guidance on demonstration of bioequivalence

Compilation of individual product-specific guidance on demonstration of bioequivalence 17 December 2014 EMA/CHMP/736403/2014 Committee for Medicinal Products for Human Use (CHMP) Compilation of individual product-specific guidance on demonstration of bioequivalence Initial batch of individual

More information

Agencia Española de Medicamentos y Productos Sanitarios C/Campezo 1, Edificio 8 28022 Madrid España (Reference Member State)

Agencia Española de Medicamentos y Productos Sanitarios C/Campezo 1, Edificio 8 28022 Madrid España (Reference Member State) DEPARTAMENTO DE MEDICAMENTOS VETERINARIOS Medicamentos y Productos C/Campezo 1, Edificio 8 28022 Madrid España (Reference Member State) DECENTRALISED PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR

More information

FRENCH AGENCY FOR VETERINARY MEDICINAL PRODUCTS DECENTRALISED PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT

FRENCH AGENCY FOR VETERINARY MEDICINAL PRODUCTS DECENTRALISED PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT FRENCH AGENCY FOR VETERINARY MEDICINAL PRODUCTS DECENTRALISED PROCEDURE FOR A VETERINARY MEDICINAL PRODUCT VIRBAKOR 20 mg film-coated tablet for dogs Date: 03/11/2014 French agency for food, environnemental

More information

Public Assessment Report. Scientific discussion. Pantoprazol Beximco 20 mg and 40 mg, gastro-resistant tablets. (pantoprazole) NL/H/2751/001-002/DC

Public Assessment Report. Scientific discussion. Pantoprazol Beximco 20 mg and 40 mg, gastro-resistant tablets. (pantoprazole) NL/H/2751/001-002/DC Public Assessment Report Scientific discussion Pantoprazol Beximco 20 mg and 40 mg, gastro-resistant tablets (pantoprazole) NL/H/2751/001-002/DC Date: 27 August 2014 This module reflects the scientific

More information

Volume 2B Notice to Applicants. Medicinal products for human use. Presentation and format of the dossier. Common Technical Document (CTD)

Volume 2B Notice to Applicants. Medicinal products for human use. Presentation and format of the dossier. Common Technical Document (CTD) Volume 2B Notice to Applicants Medicinal products for human use Presentation and format of the dossier Common Technical Document (CTD) Introduction Edition June 26 Module 1 Edition May 28 Module 2 Edition

More information

Public Assessment Report. Scientific discussion. Atorvastatine Glob 10 mg,20 mg, 40 mg, and 80 mg, film-coated tablets

Public Assessment Report. Scientific discussion. Atorvastatine Glob 10 mg,20 mg, 40 mg, and 80 mg, film-coated tablets Public Assessment Report Scientific discussion Atorvastatine Glob 10 mg,20 mg, 40 mg, and 80 mg, film-coated tablets (Atorvastatin calcium trihydrate) NL/H/2994/001-004/DC Date: 16 March 2015 This module

More information

Public Assessment Report Scientific discussion. Tostrex (Testosterone) SE/H/571/01

Public Assessment Report Scientific discussion. Tostrex (Testosterone) SE/H/571/01 Public Assessment Report Scientific discussion Tostrex (Testosterone) SE/H/571/01 This module reflects the scientific discussion for the approval of Tostrex. The procedure was finalised at 2006-04-07.

More information

EU DIRECTIVE ON GOOD CLINICAL PRACTICE IN CLINICAL TRIALS DH & MHRA BRIEFING NOTE

EU DIRECTIVE ON GOOD CLINICAL PRACTICE IN CLINICAL TRIALS DH & MHRA BRIEFING NOTE EU DIRECTIVE ON GOOD CLINICAL PRACTICE IN CLINICAL TRIALS DH & MHRA BRIEFING NOTE Purpose 1. The Clinical Trials Directive 2001/20/EC heralds certain additional responsibilities for the Medicines and Healthcare

More information

Public Assessment Report. Scientific discussion. Rivamylan 4.6 mg /24 hours and 9.5 mg /24 hours, transdermal patches.

Public Assessment Report. Scientific discussion. Rivamylan 4.6 mg /24 hours and 9.5 mg /24 hours, transdermal patches. Public Assessment Report Scientific discussion Rivamylan 4.6 mg /24 hours and 9.5 mg /24 hours, transdermal patches (rivastigmine) NL/H/2958/001-002/DC Date: 30 March 2015 This module reflects the scientific

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Food-Effect Bioavailability and Fed Bioequivalence Studies U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER)

More information

Decentralised Procedure. Public Assessment Report. Leflunomide DE/H/2609/001-002/DC. Applicants: M.R. Pharma GmbH

Decentralised Procedure. Public Assessment Report. Leflunomide DE/H/2609/001-002/DC. Applicants: M.R. Pharma GmbH Bundesinstitut für Arzneimittel und Medizinprodukte Decentralised Procedure Public Assessment Report Leflunopharm 10 mg Filmtabletten Leflunomide DE/H/2609/001-002/DC Applicants: M.R. Pharma GmbH

More information

Somulose, 400 mg/25 mg/ml, Avlivningsvätska för djur Secobarbital Sodium. Applicant: Dechra Limited

Somulose, 400 mg/25 mg/ml, Avlivningsvätska för djur Secobarbital Sodium. Applicant: Dechra Limited NATIONAL PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT Somulose, 400 mg/25 mg/ml, Avlivningsvätska för djur Secobarbital Sodium Applicant: Dechra Limited Postadress/Postal

More information

UKPAR Goodnight THR 00904/0003. Goodnight THR 00904/0003 UKPAR TABLE OF CONTENTS. Lay Summary Page 2. Scientific discussion Page 3

UKPAR Goodnight THR 00904/0003. Goodnight THR 00904/0003 UKPAR TABLE OF CONTENTS. Lay Summary Page 2. Scientific discussion Page 3 Goodnight THR 00904/0003 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 12 Steps taken after authorisation Page 13 Summary of Product Characteristics

More information

Clinical Study Synopsis for Public Disclosure

Clinical Study Synopsis for Public Disclosure abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of the clinical

More information

Public Assessment Report. Scientific discussion

Public Assessment Report. Scientific discussion Public Assessment Report Scientific discussion 1) Risedronat Actavis 5 mg Filmtabletten, 30 mg Filmtabletten, 35 mg einmal wöchentlich Filmtabletten 2) Bifodron 5 mg Filmtabletten, 30 mg Filmtabletten,

More information

Regulations for Handling Samples and Laboratory Testing from R&D through Phase III Clinical Trials

Regulations for Handling Samples and Laboratory Testing from R&D through Phase III Clinical Trials Regulations for Handling Samples and Laboratory Testing from R&D through Phase III Clinical Trials Ron Hinkel, Director Quality Systems BioReliance Inc. Patti Rossman, President Globiox Purpose Keep pace

More information

Session 6: WHO Prequalification Programme. Key Process Steps WHO: Medicines UNFPA: Condoms and IUDs

Session 6: WHO Prequalification Programme. Key Process Steps WHO: Medicines UNFPA: Condoms and IUDs Session 6: WHO Prequalification Programme Key Process Steps WHO: Medicines UNFPA: Condoms and IUDs Session adapted from the WHO training workshop on prequalification and the WHO technical briefing seminar

More information

Detach Patient's Instructions for Use from package insert and dispense with the product.

Detach Patient's Instructions for Use from package insert and dispense with the product. Attention Health Care Professional: Detach Patient's Instructions for Use from package insert and dispense with the product. PROVENTIL HFA (albuterol sulfate) Inhalation Aerosol FOR ORAL INHALATION ONLY

More information

Public Assessment Report. Pharmacy to General Sales List Reclassification. Pirinase Hayfever Relief for Adults 0.05% Nasal Spray.

Public Assessment Report. Pharmacy to General Sales List Reclassification. Pirinase Hayfever Relief for Adults 0.05% Nasal Spray. Public Assessment Report Pharmacy to General Sales List Reclassification Pirinase Hayfever Relief for Adults 0.05% Nasal Spray (Fluticasone) PL 00079/0688 Glaxo Wellcome UK Limited TABLE OF CONTENTS Introduction

More information

Guidance on Investigational Medicinal Products (IMPs) and other medicinal products used in Clinical Trials

Guidance on Investigational Medicinal Products (IMPs) and other medicinal products used in Clinical Trials EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Guidance on Investigational Medicinal Products (IMPs) and other medicinal products used in Clinical Trials

More information

DESCRIPTION OF THE MEDICINES FOR HUMAN USE (CLINICAL TRIALS) REGULATIONS 2004

DESCRIPTION OF THE MEDICINES FOR HUMAN USE (CLINICAL TRIALS) REGULATIONS 2004 DESCRIPTION OF THE MEDICINES FOR HUMAN USE (CLINICAL TRIALS) REGULATIONS 2004 Page 1 of 17 TABLE OF CONTENTS INTRODUCTION 4 EXECUTIVE SUMMARY 4 PUBLIC HEALTH BENEFITS 5 Good clinical practice 5 Good manufacturing

More information

Letter Date March 27, 2007 Stamp Date March 28, 2007 PDUFA Goal Date January 28, 2008

Letter Date March 27, 2007 Stamp Date March 28, 2007 PDUFA Goal Date January 28, 2008 CLINICAL REVIEW Application Type NDA Submission Number 22-157 Submission Code Letter Date March 27, 2007 Stamp Date March 28, 2007 PDUFA Goal Date January 28, 2008 Reviewer Name Review Completion Date

More information

Guide to Fees for Veterinary Products

Guide to Fees for Veterinary Products Guide to Fees for Veterinary Products FIN-G0003-14 04 FEBRUARY 2016 This guide does not purport to be an interpretation of law and/or regulations and is for guidance purposes only. CONTENTS ABBREVIATIONS

More information

Regulatory approval routes in the European System for Medicinal Products

Regulatory approval routes in the European System for Medicinal Products Regulatory approval routes in the European System for Medicinal Products Cardiovascular Combination Pharmacotherapy Global Summit, Melbourne, 8 th May 2014 Presented by: Kevin Blake Human Medicines Research

More information

EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL. Brussels, ENTR/CT 1. Revision 1

EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL. Brussels, ENTR/CT 1. Revision 1 EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Single market : management & legislation for consumer goods Pharmaceuticals : regulatory framework and market authorisations Brussels, ENTR/CT 1 Revision

More information

Hybrid or Mixed Marketing Authorization Application in the European Union: Not a Trivial Decision in New Development Programs for Established Drugs

Hybrid or Mixed Marketing Authorization Application in the European Union: Not a Trivial Decision in New Development Programs for Established Drugs Hybrid or Mixed Marketing Authorization Application in the European Union: Not a Trivial Decision in New Development Programs for Established Drugs Drug Information Journal 00(0) 1-6 ª The Author(s) 2012

More information

Definition of Investigational Medicinal Products (IMPs) Definition of Non Investigational Medicinal Products (NIMPs)

Definition of Investigational Medicinal Products (IMPs) Definition of Non Investigational Medicinal Products (NIMPs) EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Definition of Investigational Medicinal Products (IMPs) Definition of Non Investigational Medicinal Products

More information

Guide to Clinical Trial Applications

Guide to Clinical Trial Applications Guide to Clinical Trial Applications AUT-G0001-9 DATE 29 JUNE 2015 This guide does not purport to be an interpretation of law and/or regulations and is for guidance purposes only. CONTENTS ABBREVIATIONS

More information

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Health systems and products Medicinal products authorisations, EMA Brussels, 27.03.2014 ENTR/6283/00 Rev 4 orphan\guidelines\format content

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON SIMILAR BIOLOGICAL MEDICINAL PRODUCTS

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON SIMILAR BIOLOGICAL MEDICINAL PRODUCTS European Medicines Agency Evaluation of Medicines for Human Use CHMP/437/04 London, 30 October 2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON SIMILAR BIOLOGICAL MEDICINAL PRODUCTS

More information

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS (CVMP)

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS (CVMP) European Medicines Agency Veterinary Medicines and Inspections London, 15 April 2005 EMEA/CVMP/134/02 Rev 1 CPMP/QWP/227/02 Rev 1 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) COMMITTEE FOR VETERINARY

More information

Comparative analysis between the possible regulatory approaches to GMP compliance TITOLO PRESENTAZIONE

Comparative analysis between the possible regulatory approaches to GMP compliance TITOLO PRESENTAZIONE Comparative analysis between the possible regulatory approaches to GMP compliance TITOLO PRESENTAZIONE Dr. Fulvio CARLOTTI, GNOSIS SpA, Corporate QA Director September 26, 2014 Scope of GMP GMP compliance

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

UK Implementation of the EU Clinical Trial Directive 2001/20/EC:

UK Implementation of the EU Clinical Trial Directive 2001/20/EC: UK Implementation of the EU Clinical Trial Directive 2001/20/EC: GCP Aspects. Dr. Colin Wilsher, FRQA. BARQA GCP Committee Chairman; & Pfizer Worldwide Development Quality Assurance. GIQAR, Roma, October

More information

OECD Recommendation on the Governance of Clinical Trials

OECD Recommendation on the Governance of Clinical Trials OECD Recommendation on the Governance of Clinical Trials Marketing authorisation status of the medicinal products Non-authorised medicine Authorised medicine, treatment regimen outside

More information

EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL. Brussels, ENTR/F2/BL D(2003) CT 1 Revision 2

EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL. Brussels, ENTR/F2/BL D(2003) CT 1 Revision 2 EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Single market : management & legislation for consumer goods Pharmaceuticals : regulatory framework and market authorisations Brussels, ENTR/F2/BL D(2003)

More information

Opinion/ Commission. Notification. Decision. Issued 2 / affected 3 amended on. 30/07/2015 Annex II, Labelling and PL

Opinion/ Commission. Notification. Decision. Issued 2 / affected 3 amended on. 30/07/2015 Annex II, Labelling and PL Procedural steps taken and scientific information after the authorisation Application Scope Opinion/ Commission Product Summary number Notification Decision Information 1 issued on Issued 2 / affected

More information

Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues

Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues 1 2 3 03 June May 2013 EMEA/CHMP/BMWP/42832/2005 Rev. 1 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 7 Guideline on similar biological medicinal products containing biotechnology-derived

More information

Sheffield Kidney Institute. Planning a Clinical Trial

Sheffield Kidney Institute. Planning a Clinical Trial Planning a Clinical Trial Clinical Trials Testing a new drug Ethical Issues Liability and Indemnity Trial Design Trial Protocol Statistical analysis Clinical Trials Phase I: Phase II: Phase III: Phase

More information

medicineupdate to find out more about this medicine

medicineupdate to find out more about this medicine medicineupdate Asking the right questions about new medicines Seretide for chronic obstructive pulmonary disease What this medicine is 1 What this medicine treats 2 Other medicines available for this condition

More information

EXPERT REVIEW PANEL PROCEDURE: ADDITIONAL SUPPORT TO PROCUREMENT AGENCIES UNDER EXCEPTIONAL CIRCUMSTANCES

EXPERT REVIEW PANEL PROCEDURE: ADDITIONAL SUPPORT TO PROCUREMENT AGENCIES UNDER EXCEPTIONAL CIRCUMSTANCES EXPERT REVIEW PANEL PROCEDURE: ADDITIONAL SUPPORT TO PROCUREMENT AGENCIES UNDER EXCEPTIONAL CIRCUMSTANCES Introduction The WHO Prequalification of Medicines Programme (PQP) was established to provide UN

More information

Questions & answers on signal management

Questions & answers on signal management 23 October 2015 EMA/261758/2013 Inspections and Human Medicines Pharmacovigilance Division This document addresses a number of questions which stakeholders, in particular marketing authorisation holders

More information

Guide to The Notification System for Exempt Medicinal Products

Guide to The Notification System for Exempt Medicinal Products Guide to The Notification System for Exempt Medicinal Products AUT-G0090-1 10 JULY 2014 This guide does not purport to be an interpretation of law and/or regulations and is for guidance purposes only.

More information

Draft guidance for registered pharmacies preparing unlicensed medicines

Draft guidance for registered pharmacies preparing unlicensed medicines Draft guidance for registered pharmacies preparing unlicensed medicines January 2014 1 The General Pharmaceutical Council is the regulator for pharmacists, pharmacy technicians and registered pharmacies

More information

Overview of Authorisation Procedures for Medicinal Products

Overview of Authorisation Procedures for Medicinal Products Overview of Authorisation Procedures for Medicinal Products Updated by Martha Anna Bianchetto, PharmD, MBA OBJECTIVES q q Gain an understanding of the regulatory procedures necessary to grant a medicinal

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Q2B Validation of Analytical Procedures: Methodology November 1996 ICH Guidance for Industry Q2B Validation of Analytical Procedures: Methodology Additional copies are available from:

More information

Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues

Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues 18 December 2014 EMEA/CHMP/BMWP/42832/2005 Rev1 Committee for Medicinal Products for Human Use (CHMP) Guideline on similar biological medicinal products containing biotechnology-derived proteins as active

More information

General Principles for the Safety Assessment of Excipients

General Principles for the Safety Assessment of Excipients General Principles for the Safety Assessment of Excipients General Characteristics of the Pharmaceutical Excipients Classification of excipients The Safety Assessment of Pharmaceutical Excipients : how

More information

A 4.5 Validity Period of a Marketing Authorisation

A 4.5 Validity Period of a Marketing Authorisation 104 A 4.5 Examples of situations in which the notification procedure according to Art. 61(3) of the Community Code will apply are as follows: Minor changes to the package leaflet resulting from readability

More information

EU Clinical Trials Register

EU Clinical Trials Register EU Clinical Trials Register Disclaimer: The explanations are provided for the benefit of public users of the system and to enhance general understanding of terms used. They are not intended as the regulatory

More information

Annex 6. Guidance on variations to a prequalified product dossier. Preface

Annex 6. Guidance on variations to a prequalified product dossier. Preface Annex 6 Guidance on variations to a prequalified product dossier Preface This guidance document was technically and structurally inspired by the Guideline on dossier requirements for type IA and IB notifi

More information

Food, Medicine and Health Care Administration and Control Authority

Food, Medicine and Health Care Administration and Control Authority Food, Medicine and Health Care Administration and Control Authority Bio equivalence Study Registration Requirements in Ethiopia (Four Countries Experience) Mengistab W.Aregay (Bpharm, MSc. in Health Monitoring

More information

Standard Operating Procedure. Clinical Trial Authorisation

Standard Operating Procedure. Clinical Trial Authorisation Standard Operating Procedure for Clinical Trial Authorization Scope This SOP has been written to describe the procedure undertaken to apply for Clinical Trial Authorisation from Competent Authorities in

More information

SERETIDE Fluticasone propionate/salmeterol xinafoate Consumer Medicine Information

SERETIDE Fluticasone propionate/salmeterol xinafoate Consumer Medicine Information SERETIDE Fluticasone propionate/salmeterol xinafoate Consumer Medicine Information What is in this leaflet Please read this leaflet carefully before you start using Seretide. This leaflet answers some

More information

Detailed guidance on the European clinical trials database (EUDRACT Database)

Detailed guidance on the European clinical trials database (EUDRACT Database) EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Single market : management & legislation for consumer goods Pharmaceuticals : regulatory framework and market authorisations Brussels, ENTR/F2/BL D(2003)

More information

SPECIFICATIONS AND CONTROL TESTS ON THE FINISHED PRODUCT

SPECIFICATIONS AND CONTROL TESTS ON THE FINISHED PRODUCT SPECIFICATIONS AND CONTROL TESTS ON THE FINISHED PRODUCT Guideline Title Specifications and Control Tests on the Finished Product Legislative basis Directive 75/318/EEC as amended Date of first adoption

More information

Prof. Florian Gantner. Vice President Respiratory Diseases Research Boehringer Ingelheim

Prof. Florian Gantner. Vice President Respiratory Diseases Research Boehringer Ingelheim Prof. Florian Gantner Vice President Respiratory Diseases Research Boehringer Ingelheim Research and Development in Practice: COPD Chronic Obstructive Pulmonary Disease (COPD) Facts Main cause of COPD

More information

Guidance notes on collection of drug safety information by employees and agents of pharmaceutical companies

Guidance notes on collection of drug safety information by employees and agents of pharmaceutical companies Guidance notes on collection of drug safety information by employees and agents of pharmaceutical companies March 2013 Guidance notes on collection of drug safety information by employees and agents of

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) REFLECTION PAPER

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) REFLECTION PAPER European Medicines Agency London 23 April 2009 EMEA/CHMP/BMWP/102046/2006 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) REFLECTION PAPER NON-CLINICAL AND CLINICAL DEVELOPMENT OF SIMILAR MEDICINAL

More information

IMPURITIES IN NEW DRUG PRODUCTS

IMPURITIES IN NEW DRUG PRODUCTS INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE IMPURITIES IN NEW DRUG PRODUCTS Q3B(R2) Current

More information

Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (revision 1)

Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (revision 1) 22 May 2014 EMA/CHMP/BWP/247713/2012 Committee for Medicinal Products for Human Use (CHMP) Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance:

More information

Guidance for Industry. Integration of Dose-Counting Mechanisms into MDI Drug Products

Guidance for Industry. Integration of Dose-Counting Mechanisms into MDI Drug Products Guidance for Industry Integration of Dose-Counting Mechanisms into MDI Drug Products U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER)

More information

Having regard to the Treaty establishing the European Community, and in particular Article 95 thereof,

Having regard to the Treaty establishing the European Community, and in particular Article 95 thereof, L 121/34 DIRECTIVE 2001/20/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to

More information

Guideline on stability testing for applications for variations to a marketing authorisation

Guideline on stability testing for applications for variations to a marketing authorisation 21 March 2014 EMA/CHMP/CVMP/QWP/441071/2011- Rev.2 Committee for Medicinal Products for Human Use (CHMP)/ Committee for Medicinal Products for Veterinary Use (CVMP) Guideline on stability testing for applications

More information

Guidance for Industry Labeling for Bronchodilators: Cold, Cough, Allergy, Bronchodilator,

Guidance for Industry Labeling for Bronchodilators: Cold, Cough, Allergy, Bronchodilator, Reprinted from FDA s website by Guidance for Industry Labeling for Bronchodilators: Cold, Cough, Allergy, Bronchodilator, Guidance And Antiasthmatic for Drug Industry Products for Over-the-Counter Labeling

More information

REGULATION (EEC) No 2309/93

REGULATION (EEC) No 2309/93 REGULATION (EEC) No 2309/93 Council Regulation (EEC) No 2309/93 of 22 July 1993 laying down Community procedures for the authorization and supervision of medicinal products for human and veterinary use

More information

This document is meant purely as a documentation tool and the institutions do not assume any liability for its contents

This document is meant purely as a documentation tool and the institutions do not assume any liability for its contents 2001L0020 EN 07.08.2009 002.001 1 This document is meant purely as a documentation tool and the institutions do not assume any liability for its contents B DIRECTIVE 2001/20/EC OF THE EUROPEAN PARLIAMENT

More information

Compare the physiologic responses of the respiratory system to emphysema, chronic bronchitis, and asthma

Compare the physiologic responses of the respiratory system to emphysema, chronic bronchitis, and asthma Chapter 31 Drugs Used to Treat Lower Respiratory Disease Learning Objectives Describe the physiology of respirations Compare the physiologic responses of the respiratory system to emphysema, chronic bronchitis,

More information

Humulin (LY041001) Page 1 of 1

Humulin (LY041001) Page 1 of 1 (LY041001) These clinical study results are supplied for informational purposes only in the interests of scientific disclosure. They are not intended to substitute for the FDA-approved package insert or

More information

The compassionate use of medicinal products.

The compassionate use of medicinal products. The compassionate use of medicinal products. The French ATU system C. Bélorgey Head of Department of evaluation of Clinical Trials and Medicinal products of special status ECRD 23 May 2012 Disclaimer Employee

More information

PROPOSED UPDATED TEXT FOR WHO GOOD MANUFACTURING PRACTICES FOR PHARMACEUTICAL PRODUCTS: MAIN PRINCIPLES (JANUARY 2013)

PROPOSED UPDATED TEXT FOR WHO GOOD MANUFACTURING PRACTICES FOR PHARMACEUTICAL PRODUCTS: MAIN PRINCIPLES (JANUARY 2013) January 2013 RESTRICTED PROPOSED UPDATED TEXT FOR WHO GOOD MANUFACTURING PRACTICES FOR PHARMACEUTICAL PRODUCTS: MAIN PRINCIPLES (JANUARY 2013) DRAFT FOR COMMENTS Please address any comments on this proposal

More information

EBE Position paper on labelling of biosimilars Summary of Product Characteristics (SmPC) and Patient Information Leaflet (PIL)- draft April 2013

EBE Position paper on labelling of biosimilars Summary of Product Characteristics (SmPC) and Patient Information Leaflet (PIL)- draft April 2013 FINAL EBE 21 August 2013 EBE Position paper on labelling of biosimilars Summary of Product Characteristics (SmPC) and Patient Information Leaflet (PIL)- draft April 2013 Introduction This document seeks

More information

Archiving of Clinical Trial Data and Essential Documentation JCTO/CT/SOP 4.0. Joint Clinical Trials Office. Stuart Hatcher, JCTO Archivist

Archiving of Clinical Trial Data and Essential Documentation JCTO/CT/SOP 4.0. Joint Clinical Trials Office. Stuart Hatcher, JCTO Archivist Archiving of Clinical Trial Data and Essential Documentation Policy Details Document Type Standard Operating Procedure Document name Change History Date Version Number JCTO/CT/SOP 4.0 Version Final v 2.0-09/11/2010

More information

Guideline on good pharmacovigilance practices (GVP)

Guideline on good pharmacovigilance practices (GVP) 22 June 2012 EMA/827661/2011 Guideline on good pharmacovigilance practices (GVP) Module IX Signal management Draft finalised by the Agency in collaboration with Member States and submitted to ERMS FG 19

More information

Summary of the risk management plan (RMP) for Ofev (nintedanib)

Summary of the risk management plan (RMP) for Ofev (nintedanib) EMA/738120/2014 Summary of the risk management plan (RMP) for Ofev (nintedanib) This is a summary of the risk management plan (RMP) for Ofev, which details the measures to be taken in order to ensure that

More information

RAPID ALERT SYSTEM (RAS) IN PHARMACOVIGILANCE

RAPID ALERT SYSTEM (RAS) IN PHARMACOVIGILANCE 3BC6a RAPID ALERT SYSTEM (RAS) IN PHARMACOVIGILANCE Guideline Title Rapid Alert System (RAS) in Pharmacovigilance Legislative basis Directive 65/65/EEC as amended, Council Regulation 2309/93 Date of first

More information

Annex 7 Guidelines on pre-approval inspections

Annex 7 Guidelines on pre-approval inspections World Health Organization WHO Technical Report Series, No. 902, 2002 Annex 7 Guidelines on pre-approval inspections 1. General 94 2. Glossary 94 3. Objectives 95 4. Priorities 96 5. Preparation for the

More information

Stakeholder Meeting, 7 th June 2013 An inspector s perspective considerations for patient support and reimbursement programmes

Stakeholder Meeting, 7 th June 2013 An inspector s perspective considerations for patient support and reimbursement programmes Stakeholder Meeting, 7 th June 2013 An inspector s perspective considerations for patient support and reimbursement programmes Dr Anya Sookoo, Expert Inspector, Inspections, Enforcement & Standards Division,

More information

Package leaflet: Information for the patient. Naloxone Hydrochloride 20 micrograms / ml Solution for Injection Naloxone hydrochloride

Package leaflet: Information for the patient. Naloxone Hydrochloride 20 micrograms / ml Solution for Injection Naloxone hydrochloride A leaflet will be included in each pack. The leaflet will consist of a Technical Information Leaflet and a Patient Information Leaflet. The two leaflets will be easily separatable. The text of the Technical

More information

Package leaflet: Information for the patient. Bricanyl Tablets 5 mg terbutaline sulfate

Package leaflet: Information for the patient. Bricanyl Tablets 5 mg terbutaline sulfate Package leaflet: Information for the patient Bricanyl Tablets 5 mg terbutaline sulfate Read all of this leaflet carefully before you start taking this medicine because it contains important information

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE PHARMACEUTICAL QUALITY OF INHALATION AND NASAL PRODUCTS

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE PHARMACEUTICAL QUALITY OF INHALATION AND NASAL PRODUCTS European Medicines Agency Inspections London, 21 June 2006 Doc Ref.: EMEA/CHMP/QWP/49313/2005 Corr COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE PHARMACEUTICAL QUALITY OF INHALATION

More information

June 2010 Pharmacy Professional

June 2010 Pharmacy Professional f e at u r e s p e c i a l s Dealing with specials Responding to members requests the Society presents practical guidance for pharmacists on professional responsibilities when dealing with the supply of

More information

Biologics Biosimilars

Biologics Biosimilars Biologics Biosimilars Q u e st i o n s Po l i c y S a fe t y What are biosimilars? Biosimilars are sometimes incorrectly and inappropriately called generic versions of original biological medicines. But

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON RISK MANAGEMENT SYSTEMS FOR MEDICINAL PRODUCTS FOR HUMAN USE

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON RISK MANAGEMENT SYSTEMS FOR MEDICINAL PRODUCTS FOR HUMAN USE European Medicines Agency Post-authorisation Evaluation of Medicines for Human Use London, 14 November 2005 Doc. Ref. EMEA/CHMP/96268/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE

More information

Public Assessment Report Scientific discussion. Medicinsk lustgas Yara Industrial, 100% medicinal gas, liquefied Nitrous oxide SE/H/659/01/DC

Public Assessment Report Scientific discussion. Medicinsk lustgas Yara Industrial, 100% medicinal gas, liquefied Nitrous oxide SE/H/659/01/DC Public Assessment Report Scientific discussion Medicinsk lustgas Yara Industrial, 100% medicinal gas, liquefied Nitrous oxide SE/H/659/01/DC This module reflects the scientific discussion for the approval

More information

Better Breathing with COPD

Better Breathing with COPD Better Breathing with COPD People with Chronic Obstructive Pulmonary Disease (COPD) often benefit from learning different breathing techniques. Pursed Lip Breathing Pursed Lip Breathing (PLB) can be very

More information

Preparation of a Meaningful and Appropriate Risk Management Plan a Multifunctional Task. Wissenschaftliche Prüfungsarbeit. zur Erlangung des Titels

Preparation of a Meaningful and Appropriate Risk Management Plan a Multifunctional Task. Wissenschaftliche Prüfungsarbeit. zur Erlangung des Titels Preparation of a Meaningful and Appropriate Risk Management Plan a Multifunctional Task Wissenschaftliche Prüfungsarbeit zur Erlangung des Titels Master of Drug Regulatory Affairs der Mathematisch-Naturwissenschaftlichen

More information

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Ref. Ares(2011)1044649-03/10/2011 EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Health systems and products Pharmaceuticals SANCO/D3/RSR/iv(2011)ddg1.d3. 1137738 Update 1 October 2011 HANDLING

More information